ライフサイエンスコーパス: renal transplant patient

1 essed, human immunodeficiency virus-negative renal transplant patient.

2 s and hemophagocytic syndrome in an asplenic renal transplant patient.

3 ng adult care is a vulnerable period for the renal transplant patient.

4 reviously unknown poxvirus rash illness in a renal transplant patient.

5 igen (HLA) antibodies (dnDSA) in the primary renal transplant patient.

6 ey allograft survival affecting up to 15% of renal transplant patients.

7 disease in immunosuppressed bone marrow and renal transplant patients.

8 spective study was undertaken in MMF-treated renal transplant patients.

9 alysis was used to estimate lymphoma risk in renal transplant patients.

10 ne and steroids as a maintenance regimen for renal transplant patients.

11 es and CNI toxicity after the first month in renal transplant patients.

12 L10 for detecting alloimmune inflammation in renal transplant patients.

13 , to cynomolgus monkeys and most recently to renal transplant patients.

14 netics of multiple doses of FTY720 in stable renal transplant patients.

15 for following the course of the infection in renal transplant patients.

16 iovascular risk attributable to BP burden in renal transplant patients.

17 he prevention of acute rejection episodes in renal transplant patients.

18 tilymphocyte antibody-resistant rejection in renal transplant patients.

19 ute to posttransplant bone loss in long-term renal transplant patients.

20 cause of renal allograft failure among adult renal transplant patients.

21 e in preventing acute rejection in cadaveric renal transplant patients.

22 uggest its use in the clinical management of renal transplant patients.

23 available than cyclosporine (CsA) in de novo renal transplant patients.

24 as a routine HLA antibody screening test for renal transplant patients.

25 t hypertension in cyclosporine (CsA)-treated renal transplant patients.

26 levels within the therapeutic range of human renal transplant patients.

27 osporine, in the postoperative management of renal transplant patients.

28 n cyclosporine A (CsA) bioavailability in 10 renal transplant patients.

29 stimating measured GFR (mGFR) changes in 110 renal transplant patients.

30 would guide immunosuppression management in renal transplant patients.

31 , and kidney biopsies were collected from 48 renal transplant patients.

32 d GC-MS-based metabolomic study on urines of renal transplant patients.

33 y of monitoring immunosuppressive therapy in renal transplant patients.

34 oming the standard of care for KS arising in renal transplant patients.

35 ion profile, a finding that was confirmed in renal transplant patients.

36 ociodemographic and clinical risk factors in renal transplant patients.

37 e vulgares and molluscum lesions in all four renal transplant patients.

38 reference tacrolimus (Prograf(R)) in stable renal transplant patients.

39 increased TNF-alpha when compared to stable renal transplant patients.

40 implications for the clinical management of renal transplant patients.

41 f the NFATc4 gene were genotyped in Hispanic renal transplant patients.

42 hr urine albumin excretion (n=189) in stable renal transplant patients.

43 ated with only two cases of disease, both in renal transplant patients.

44 dence and risk factors of NODAT in pediatric renal transplant patients.

45 irolimus (SRL) can improve graft function in renal transplant patients.

46 therapy is safe in immunologically high-risk renal transplant patients.

47 ons of new-onset diabetes mellitus (NODM) in renal transplant patients.

48 Hyperlipidemia affects the majority of renal transplant patients.

49 s or Neoral as primary immunosuppressant for renal-transplant patients.

50 This study involved 39 renal transplant patients (19 cadaveric and 20 living do

51 se in control subjects (-19.8+/-3.0 bpm) and renal transplant patients (-23.9+/-4.9 bpm) (P<.001 vers

52 Viral DNA was present in the blood of some renal transplant patients (3/33 PCR-positive) but in non

53 titutions have reported favorable results in renal transplant patients after conversion from cyclospo

54 cyte antigen (HLA)-specific B lymphocytes in renal transplant patients after treatment with B-lymphoc

55 proved for prophylaxis of acute rejection in renal transplant patients aged 13 years or older.

56 ctional, interview study was conducted among renal transplant patients aged 20 to 30 years.

57 of human herpesvirus 8 (HHV-8) activation in renal transplant patients, an immunocompromised populati

58 Microscopic examination of stool from one renal transplant patient and of tracheal and gastric asp

59 idomic analysis of 70 unique samples from 50 renal transplant patients and 20 controls (n = 20), iden

60 ctive observational and database analysis of renal transplant patients and a physician questionnaire

61 ications of nonspecific immunosuppression in renal transplant patients and accounts for significant m

62 cytomegalovirus (CMV) disease in a group of renal transplant patients and assessed the role of viral

63 The primary toxicity was anemia in the renal transplant patients and elevation of liver enzymes

64 auses polyomavirus-associated nephropathy in renal transplant patients and hemorrhagic cystitis in bo

65 tion is associated with inferior survival in renal transplant patients, and ganciclovir (GCV) prophyl

66 r) in a large, inclusive survey (n = 172) in renal transplant patients at a single institution.

67 ty-four urine samples were collected from 32 renal transplant patients at various stages posttranspla

68 d educators need to take explicit account of renal transplant patients' attitudes when evaluating ris

69 formulation is similar to Prograf in stable renal transplant patients, but data in de novo patients

70 idence of ischemic heart disease (IHD) among renal transplant patients can be attributed to the same

71 xpression data in 558 blood samples from 436 renal transplant patients collected across eight transpl

72 on does not offer a better GFR prediction in renal transplant patients compared with the MDRD Study e

73 A renal transplant patient developed chronic and progressi

74 dialysis patients is exceeded by that among renal transplant patients during the first 1 to 3 years

75 chocardiography) assessment were done in 165 renal transplant patients during the first year and afte

76 converting from Tac BID to Tac QD in stable renal transplant patients, especially in patients with t

77 open-label, parallel-group, 6-month study in renal transplant patients, FK778 (an investigational imm

78 l records of a single-center cohort of 2,515 renal transplant patients followed for up to 22 yr.

79 Adherence Measurement in Stable Renal Transplant Patients Following Conversion From Prog

80 changes after converting stable, maintenance renal transplant patients from CsA (once daily and twice

81 en case-control pairs were created among all renal transplant patients from October 2005.

82 retrospective study of the first 75 primary renal transplant patients given alemtuzumab induction at

83 Renal transplant patients have been shown to have a high

84 ion, whereas conventionally immunosuppressed renal transplant patients homozygous for a nonfunctional

85 CMV was first isolated in a renal transplant patient in 1965,

86 trospective, case-control study examined 120 renal transplant patients in a VL endemic area.

87 mocystis isolates from 3 outbreaks of PCP in renal transplant patients in Germany, Switzerland, and J

88 Furthermore, analysis of data from 46,691 renal transplant patients in the United Network for Orga

89 y alter basal lipoprotein lipase activity in renal transplant patients in this study.

90 This study indicates that for renal transplant patients in whom RAPA treatment induces

91 l 20, 2004 and December 26, 2007 we enrolled renal transplant patients into a prospective, randomized

92 The incidence of pancreatitis in renal transplant patients is low (1%-2%), but the mortal

93 reactivation in immunosuppressed patients or renal transplant patients is the primary cause of polyom

94 tation, it is not known whether their use in renal transplant patients leads to excessive suppression

95 or precise in reflecting real GFR decline in renal transplant patients, making them unreliable for cl

96 common disease in most transplant patients, renal transplant patients more commonly experience urina

97 Twenty-five stable renal transplant patients on maintenance tacrolimus and

98 Forty renal transplant patients on Tac BID were converted on a

99 reteral ulceration with ureteral stenosis in renal transplant patients or hemorrhagic cystitis in bon

100 s. 100 days) in a cohort of 10,000 high-risk renal transplant patients over 5 and 10 years.

101 levels of catalytic IgG in a large cohort of renal transplant patients over a 2-y period.

102 aitlisted group was 9.9% compared to 1.9% in renal transplant patients (P < 0.001).

103 s that need special attention in the care of renal transplant patients, particularly modifiable facto

104 In the general renal transplant patient population, immunosuppressive r

105 ion in peripheral blood mononuclear cells of renal transplant patients (r=0.91, P<0.001).

106 Using data from 130 pediatric renal transplant patients randomized to steroid-free (SF

107 atory, randomized, 6-month study, 92 de novo renal transplant patients received everolimus, steroids,

108 -center, retrospective analysis of pediatric renal transplant patients receiving 24 weeks valganciclo

109 In renal transplant patients receiving kidneys from donors

110 of predicted alloimmune quiescence in stable renal transplant patients receiving long-term immunosupp

111 TNFR:Fc is well tolerated by renal transplant patients receiving OKT3 induction thera

112 Adult renal transplant patients receiving standard immunosuppr

113 chronic rejection by analyzing data from 245 renal transplant patients receiving Tacrolimus-based imm

114 suggest that steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based imm

115 group (P < 0.001) compared with nondiabetic renal transplant patients receiving the same immunosuppr

116 al of steroid withdrawal was conducted among renal transplant patients receiving triple immunosuppres

117 survival for both cadaveric and living-donor renal-transplant patients receiving either Neoral or tac

118 trospective cohort study of Medicare primary renal transplant patients reported in the United States

119 Eighty-three of 2989 renal transplant patients required myocardial revascular

120 which is currently a major cause of death in renal transplant patients (RTRs).

121 Of nine APAS renal-transplant patients, seven were treated with couma

122 Paricalcitol administration to renal transplant patients significantly reduced intact p

123 monitoring (ABPM) for risk stratification in renal transplant patients still remains poorly defined.

124 In renal transplant patients, TCF7L2 rs7903146 is strongly

125 We present a case of CMV vasculitis in a renal transplant patient that caused middle and left col

126 Finally, we found that in renal transplant patients, the number of endothelial mic

127 In renal transplant patients, the prevalence of nocturnal h

128 Of 41,705 Medicare primary adult renal transplant patients, there were 9.9% patients who

129 We evaluated antibody binding of waitlisted renal transplant patients to 3 glycan knockout (KO) pig

130 actic ganciclovir (GCV) is used in high-risk renal transplant patients to prevent acute cytomegalovir

131 randomized, exploratory 6-month study of 92 renal transplant patients treated de novo with concentra

132 predisposing factors for dyslipidemia among renal transplant patients treated for up to 6 years with

133 report the long-term DSA response results on renal transplant patients treated with bortezomib.

134 t doses up to 5.0 mg/day for 28 days, stable renal transplant patients treated with FTY720 in combina

135 A retrospective study in all renal transplant patients treated with tacrolimus at our

136 Two hundred thirty-six renal transplant patients underwent full dental examinat

137 vivo kinetics of lymphocytes in CMV-infected renal transplant patients using longitudinal samples com

138 roach to regulatory T-cell (Treg) therapy in renal transplant patients, using a delayed infusion prot

139 unosuppression for immunologically high-risk renal transplant patients usually involves antithymocyte

140 Twenty renal transplant patients were included in this retrospe

141 Seventy-five renal transplant patients were included, and six of them

142 Twelve stable renal transplant patients were investigated using limiti

143 The renal transplant patients were matched for donor and rec

144 Eleven hypertensive, CsA-treated renal transplant patients were placed on amlodipine for

145 Outcome differences in obese renal transplant patients were primarily due to a higher

146 Tacrolimus dose requirements of 206 stable renal transplant patients were related to MDR-1 genotype

147 Thirteen living donor renal transplant patients were treated with bortezomib o

148 After cadaveric renal transplant, patients were randomized to receive ta

149 We report a case of a stable renal transplant patient who had a decrease in CsA conce

150 We report a renal transplant patient who presented with early onset

151 rapamycin, we have occasionally encountered renal transplant patients who develop unexpected severe

152 Unfortunately, most renal transplant patients who developed acute rejection-

153 We present five renal transplant patients who developed serum sickness a

154 The two renal transplant patients who developed Strongyloides hy

155 and HLA-DQ antigens were determined for 703 renal transplant patients who had no detectable donor-sp

156 Genotypes for 86 renal transplant patients who received SRL-based mainten

157 ose was to determine the compliance rates of renal transplant patients who received their immunosuppr

158 We identified 99 renal transplant patients who underwent an allograft bio

159 ment, by allograft autotransplantation, of a renal transplant patient with an invasive carcinoma of t

160 We present a case in a renal transplant patient with chronic skin lesions of th

161 m was used to study 37 serum samples from 15 renal transplant patients with (n=10) and without (n=5)

162 In this single-center study, 26 living-donor renal transplant patients with a positive level of de no

163 is associated with higher serum IL-17A among renal transplant patients with acute rejection, linking

164 levels were significantly elevated in human renal transplant patients with acute VR (n = 16) compare

165 l study to compare serum LG3 levels in human renal transplant patients with acute VR, tubulo-intersti

166 Renal transplant patients with adenoviral infection most

167 lasma cells, has been shown to reduce DSA in renal transplant patients with AMR.

168 inct condition which should be considered in renal transplant patients with ascites, after all other

169 y and safety of sofosbuvir and ledipasvir in renal transplant patients with chronic HCV infection.

170 s of maintenance immunosuppressive agents in renal transplant patients with chronic viral hepatitis.

171 determine changes in anti-HLA antibodies in renal transplant patients with COVID-19 and compare the

172 In renal transplant patients with de novo donor-specific an

173 In renal transplant patients with de novo DSA, microcircula

174 ipid profiles in stable cyclosporine-treated renal transplant patients with established hyperlipidemi

175 longitudinal, open-label trial, MMF-treated renal transplant patients with gastrointestinal symptoms

176 non-smokers were included (40 CsA-medicated renal transplant patients with GO [GO+; n = 20] or witho

177 tocellular carcinoma, and hepatic failure in renal transplant patients with HCV infection are scarce.

178 mportant ancillary therapy in hypomagnesemic renal transplant patients with hyperlipidemia.

179 y, no guidelines exist for the management of renal transplant patients with impaired glucose toleranc

180 Our preliminary studies in renal transplant patients with invasive fungal diseases

181 proposed as ways to prolong the survival of renal transplant patients with ischemic heart disease.

182 In non-renal transplant patients with life-sustaining organs, w

183 gree of unnoticed tacrolimus overexposure in renal transplant patients with mild diarrhea while on tr

184 flow reactivity with clinical outcome among renal transplant patients with negative preoperative cyt

185 iopsies of a well-characterized cohort of 28 renal transplant patients with no rejection (Ctrl), dela

186 that have the ability to distinguish between renal transplant patients with no rejection and those wi

187 In preliminary studies, adult renal transplant patients with normal histology (n = 5),

188 determine if any aspects of the treatment of renal transplant patients with pancreatitis were of part

189 transcripts in biopsy samples from 42 stable renal transplant patients with posttransplant hypertensi

190 hat co-infection with BKV and SV40 occurs in renal transplant patients with PVN, suggesting that SV40

191 Compared with matched controls, renal transplant patients with SLE had inferior transpla

192 the largest single medical center series of renal transplant patients with SLE, recurrent LN was mor

193 om a prospective, observational cohort of 59 renal transplant patients with surveillance or indicatio

194 udy, we assessed the outcome of all (n = 95) renal transplanted patients with pretransplant cancer di

195 uperior immunosuppressive agent in pediatric renal transplant patients, with excellent short- and med

196 n activity, was measured in stable pediatric renal transplant patients, with healthy children used as

197 Twelve patients with PTE and 12 renal transplant patients without PTE were studied.